Waldenström macroglobulinaemia is an indolent B-cell lymphoma with clearly defined
criteria for diagnosis, initiation of therapy, and response, which was established by …

Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for
which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy …

Recently, many new drugs have been developed for the treatment of Waldenström
macroglobulinemia (WM). To optimize the treatment according to the prognosis and to …

Purpose We examined the activity of bortezomib, dexamethasone, and rituximab (BDR) in
patients with symptomatic, untreated Waldenström macroglobulinemia (WM). Patients and …

Purpose Alkylating agents and the anti-CD20 monoclonal antibody rituximab are among
appropriate choices for the primary treatment of symptomatic patients with Waldenström …

Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for
which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy …

Waldenström macroglobulinemia (WM) is a distinct B-cell disorder resulting from the
accumulation, predominantly in the bone marrow, of clonally related IgM-secreting …

Most patients diagnosed with primary chronic cold agglutinin disease (CAD) have a clonal
lymphoproliferative bone marrow disorder. Treatment with rituximab is the only well …

Purpose Treatment options for patients with Waldenström macroglobulinemia (WM) and
closely related disorders include alkylating agents, purine analogs, and monoclonal …

In the past 36 months, new developments have occurred both in the understanding of the
biology of Waldenström macroglobulinemia (WM) and in therapeutic options for WM. Here …